Efficacy of 23-valent Pneumococcal Polysaccharide Vaccine in Steroid Responsive Nephrotic Syndrome.
- Author:
Hye Won HAHN
1
;
Il Soo HA
;
Hae Il CHEONG
;
Hoan Jong LEE
;
Yong CHOI
Author Information
1. Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea. ychoi@plaza.snu.ac.kr
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Nephrotic syndrome;
Peritonitis;
S. pneumoniae;
Pneumococcal vaccine
- MeSH:
Adult;
Child;
Follow-Up Studies;
Humans;
Incidence;
Medical Records;
Mortality;
Nephrotic Syndrome*;
Peritonitis;
Pneumococcal Vaccines*;
Recurrence;
Streptococcus pneumoniae
- From:Journal of the Korean Society of Pediatric Nephrology
2002;6(1):56-60
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Streptococcus pneumoniae is a major pathogen in both adults and children, causing significant morbidity and mortality. In patients with nephrotic syndrome, Streptococcus pneumoniae is a major cause of spontaneous peritonitis, and the increasing incidence of penicillin-resistance strain facilitates the development of effective vaccine. The limitation of current pneumococcal polysaccharide vaccine prompted development of polysaccharide-protein conjugate vaccine. METHODS: We reviewed the medical record of total 225 steroid responsive nephrotic patients to ascertain the effectiveness of 23-valent pneumococcal polysaccharide vaccine. RESULTS: Twenty-eight patients have developed peritonitis during the courses, and 7 of those have recurrent peritonitis. Fifty-five patients were vaccinated and followed-up for 1-108 months (mean 38.5 months), and during the follow-up period, pneumococcus related peritonitis was not detected. Vaccine-related relapse of nephrotic syndrome was absent. CONCLUSION: In spite of the non-consensus about the efficacy of PPV23, clinically it benefits, and until the clinical trial of PCV7 is completed, PPV23 will be recommended.
